{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"27.6","value":"10.4"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"15.3","value":"13.6"},{"groupId":"OG002","lowerLimit":"1.2","upperLimit":"4.8","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was calculated from the date of the first infusion to the date of documented PD or death (regardless of the reason), whichever comes first","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received plitidepsin 4 mg/m2 and BTZ 1 mg/m2 and DXM 40 mg. DXM was administered at least one hour before the start of plitidepsin infusion, and BTZ was administered one minute after the end of the plitidepsin infusion. Patients received a maximum of eight treatment cycles","id":"OG000","title":"Plitidepsin (4 mg/m2)+BTZ (1 mg/m2)+DXM (40 mg)"},{"description":"Patients received plitidepsin 4 mg/m2 and BTZ 1.3 mg/m2 and DXM 40 mg. DXM was administered at least one hour before the start of plitidepsin infusion, and BTZ was administered one minute after the end of the plitidepsin infusion. Patients received a maximum of eight treatment cycles","id":"OG001","title":"Plitidepsin (4 mg/m2)+BTZ (1.3 mg/m2)+DXM (40 mg)"},{"description":"Patients received plitidepsin 5 mg/m2 and BTZ 1.3 mg/m2 and DXM 40 mg. DXM was administered at least one hour before the start of plitidepsin infusion, and BTZ was administered one minute after the end of the plitidepsin infusion. Patients received a maximum of eight treatment cycles","id":"OG002","title":"Plitidepsin (5 mg/m2)+BTZ (1.3 mg/m2)+DXM (40 mg)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"from the date of the first infusion to the date of documented PD or death, up to 4 years","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}